Traditional imaging techniques, such as computed tomography (CT), have high spatial resolution for changes in the anatomy or structure of organs, but are not very useful for detecting early biochemical changes. Conversely, positron emission tomography (PET) relies on changes in molecular biology to identify the earliest stages of disease but, if used alone, has sub-optimal spatial delineation. However, computer-assisted fused-image and/or single-machine integrated PET-CT can show early biochemical changes with improved anatomic resolution, often before there is any structural change. This approach enables the clinician to view and assess the patient's body from a biochemical perspective. In an era of rapidly evolving 3D conformal radiation treatment, accurate target delineation is a crucial factor in optimization of clinical results. This paper reviews some of the basic-science underpinnings of PET-CT, and highlights some important findings in the early clinical work thus far performed.
Introduction
Traditional medical imaging techniques, such as x-ray, computed tomography scanning (CT), magnetic resonance imaging (MRI), and ultrasound, depend on changes in the anatomy or structure of organs. These morphologic changes can be detected with high spatial resolution (1-2 mm for CT), but early biochemical changes, that are common in neoplastic disorders, can easily avoid detection.
Conversely, positron emission tomography (PET) is a highly sensitive and accurate nuclear medicine imaging technology that relies on changes in tissue biochemistry and metabolism to identify the earliest stages of disease (1-3). Therefore, PET may result in earlier diagnosis of cancer, improved determination of primary tumor extent and regional lymphatic involvement, and detection of otherwise unseen metastases (4-5). As such, it is a powerful tool that can assist in the delineation and clinical staging of many malignancies, evaluation of treatment response, and detection of tumor recurrence (6-7). Nonetheless, this imaging technology has intrinsically lower spatial resolution (5-6 mm) , thereby resulting in suboptimal anatomic delineation of the biochemical abnormalities. With fluorodeoxyglucose (FDG) tracer, the 18 F-positron-emitting glucose analog most commonly used in PET, the only reliable anatomic markers are organs with high metabolic rate (e.g., heart) and the excretory system.
With increasing clinical acceptance of the therapeutic value of three-dimensional (3D) conformal radiation treatment delivery, e.g., proton beam and intensity modulated radiation therapy (IMRT), it has become ever more important to improve the accuracy of 3D target delineation in the treatmentplanning process.
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While computer-assisted fused images are a big step forward from side-by-side visual image comparison, integrated PET-CT scanning within a single machine has several additional advantages. Obtaining the two scans virtually simultaneously maximizes the likelihood that the patient remains in identical position and, therefore, that the two images can superimpose into a precise computer overlay. The resulting spatial registration with the integrated images is typically superior to that achieved with separate scans. This single-machine image thereby provides a more reliable alternative to the traditional side-by-side visual comparison or computer-assisted fusion of separate PET and CT images. Furthermore, this approach permits more precise photon-attenuation correction of the PET images (see below).
These qualities of integrated PET-CT scanning make it more reliable to use to determine the precise anatomic locations associated with high tracer activity, resulting in more consistent interpretation, especially in regions of complex anatomy. Furthermore, integrated scanning requires only a single scheduled procedure (8-9), and thereby eliminates the problems of repositioning and delay between the two studies, during which time the patient positioning or the tumor status may change.
In addition to these diagnostic benefits, fused-image or integrated PET-CT often helps radiation oncologists better tailor 3D radiation fields, and assists surgeons in pinpointing biopsy or excision sites. PET-CT imaging is most valuable for cancers located in regions of the body that have complex anatomy, such as the lung, head-and-neck and lower pelvis. Similarly, this technique can aid in multi-focal diseases, such as lymphoma, by providing more exact locations for biopsies and irradiation.
PET-CT: Basic Science Aspects

Molecular Biology of PET Tracer Molecules
PET utilizes the property of selective biological accumulation following IV injection that is inherent to certain molecules. The selected tracer compound is modified by the replacement of one of its atoms with a positron-emitting isotope, so that its location in the body can be imaged. Glucose is of particular interest for oncology imaging, since it is typically absorbed by cancer tissue to a greater extent than by normal tissue. FDG is a glucose analog with replacement of the oxygen in C-2 position with 18 F.
Glucose is actively transported into the cell by specific transport proteins. Once intracellular, glucose is phosphorylated into glucose-6-phosphate by hexokinase, as the first step toward glycolysis, glycogen formation or other normal pathways. Glucose-6-phosphate may also be enzymatically converted back to glucose. FDG, like glucose, is actively transported into the cell by glucose-transport proteins, and then phosphorylated by hexokinase ( Figure 1 ). At this step, however, FDG becomes effectively trapped intracellularly as FDG-6-phosphate, since the outgoing enzymatic pathways don't accept FDG as a substrate. Tumor cells often display an increased number of glucose-transport proteins, as well as higher levels of hexokinase. Additionally, they are often highly metabolically active, with increased glucose demands. Therefore, tumor cells often uptake and retain higher levels of FDG, when compared to normal tissues. This process is good for detecting disturbances in molecular biology, before there is any change in anatomy or organ structure, as might later be seen on x-ray, ultrasound, CT, or MRI. PET, especially when combined with CT, is very accurate in showing the presence or spread of many malignant tumors. For example, PET-CT is more accurate in detecting the spread of lung cancer and colorectal cancer than any other imaging method currently available (9-10).
The generic concept is that the injected tracer molecule preferentially seeks out the tumor cells, and then naturally 
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Glycolysis phosphorgluconolactose 18FDG Figure 1 : Like glucose, FDG is actively transported into the cell by a group of structurally related glucose-transport proteins. Once intracellular, FDG is also phosphorylated by hexokinase. At this step, however, FDG becomes effectively trapped intracellularly as FDG-6-phosphate, since the outgoing enzymatic pathways don't accept FDG as a substrate. Therefore, the intracellular location is the dominant site of positron-emission decay.
decays via positron release. Histologic examination is the most reliable method of delineating pathology. However, the great clinical value of PET is to provide anatomically precise delineation of pathology to a higher degree of sensitivity and specificity than can be achieved by more traditional medical imaging techniques.
While the majority of the accumulating clinical data has focused on PET's role in affecting clinical tumor staging and image-based primary tumor delineation, some studies have specifically evaluated the reliability of PET as a predictor of histopathology. In patients with clinical early-stage cervical cancer, pre-operative integrated FDG PET-CT findings were compared with the results of subsequent pelvic lymph node dissection (2). Of the total of 1081 lymph nodes sampled in 47 patients, node-specific positive predictive value (PPV), negative predictive value, and accuracy of PET-CT were 81%, 99.5%, and 99.3%, respectively. In 80 histologically confirmed breast cancer patients of presumed earlystage (clinically negative axillary lymph nodes), pre-operative FDG PET-CT findings were compared with the results of subsequent total axillary lymph node dissection (3); a PPV of 89% was demonstrated.
However, FDG is not cancer-specific, and will accumulate in areas with high levels of metabolism. Therefore, increased FDG uptake can be expected in sites of hyperactivity (e.g., muscular or nervous tissue), active inflammation (e.g., infection, arthritis, or sarcoid), or tissue repair. Other potential biological tracers include various molecules that also appear naturally in vivo, or that are known to accumulate in specific tissues, but with selected positron-emitting isotopes (Table  I ) substituted in similar fashion (e.g., 11 C, 13 N, 15 O, 18 F, 68 Ga, or 124 I). Some tumors do not use more glucose than adjacent normal tissue, but do use excess amino acids. In such cases (e.g., many brain tumors), labeled amino acids are used, such as L-[ 11 C]methionine or L-[ 18 F]fluoroethyltyrosine. Currently, numerous PET tracers other than FDG are being actively studied, and may shortly reach wider use.
Physical Properties of PET Isotopes
PET isotopes typically decay quite rapidly, many with half-lives measured in minutes (Table I) . Therefore, these isotopes must be created with a cyclotron very shortly before their use, and the isotope-containing tracer molecules must then be quickly chemically synthesized (including purification and quality control) and rapidly distributed. The most commonly used positron emitting radionuclides are carbon, nitrogen, oxygen, and fluorine. These elements are normal components of human tissue. Given their short half-lives, 11 C, 13 N, and 15 O can only be used in simple molecules, whose synthesis requires extremely fast chemical reactions and procedures. 18 F has a somewhat longer half-life; therefore, FDG is a more readily usable entity.
The positron energy upon decay ranges from 0.635 MeV ( 18 F) to 1.88 MeV ( 68 Ga), corresponding to maximum ranges of 2.4 mm to 8.1 mm in tissue medium (Table I) , although typically the positron travels less than 1-2 mm before it collides with an electron, resulting in an annihilation reaction.
Tomographic Imaging of Positron Emission
Positron emission enables tomographic imaging of the tracer distribution in the body. A positron is a particle with the same mass as an electron, but with a positive electric charge. Once emitted, a positron immediately begins to lose its kinetic energy via electromagnetic interactions with nearby molecules in the adjacent tissue. Within a few millimeters, the slowing positron collides directly with a free electron. This collision leads to a matter-antimatter mutual annihilation reaction (Figure 2 ), wherein the masses of the electron and positron are converted to electromagnetic radiation. Due to conservation of energy and momentum, two "annihilation" photons appear (two gamma rays). The total energy of these photons will equal the rest mass of the original electron and positron (511 keV) and they will be emitted in a 180 degree opposite direction to one another. 
Figure 2:
The injected tracer molecule preferentially seeks out the desired target (say, tumor cells), then naturally decays via positron release. Within a very short distance (1-2 mm), it collides with a free electron in the adjacent tissue, leading to a matter-antimatter mutual annihilation reaction, and the release of diametrically opposed 511 keV photons.
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Registration and Resolution of Fused-image and Integrated PET-CT
The positional errors that arise in coalescing data from PET and CT derive from several independent sources. These sources include errors in spatial registration of the two scans, methods of photon-attenuation correction for PET imaging, and differences in intrinsic spatial resolution between PET and CT. These physical issues are separate from the concerns about the biological sensitivity and specificity of the multiple potential tracer molecules available (and under development) for PET use.
Integrated PET-CT scanning optimizes spatial registration between the two imaging modalities. Since the patient remains in the same position throughout the integrated imaging procedure, differences of translation and of angular rotation (pitch, roll, and yaw) between the PET and the CT are minimized, as compared to that which applies when the two scans are scheduled as separate events. Another problem that is minimized with integrated scanning (compared with fusion of independent scans) is the unpredictable variability of translation and angular rotation at different regions within the body, when one scan is compared with the other. With two independent scans, subtle differences in rotation of the neck and torso may cause unexpected translational and rotational errors in different anatomic regions. With computerassisted image-fusion, therefore, separate sets of translational and angular-rotation correction for optimized image fusion may be required for multiple body regions. The improved PET-CT registration that results from an integrated scanning technique thereby improves the precision and reliability with which the PET tracer-uptake data can be represented within the anatomic domain of CT. This benefit is especially demonstrated in regions of complex anatomy.
Integrated scanning also permits very precise attenuation correction of the PET image (Figure 4 ). Positron-annihilation photons originating from structures deeper in the body are more attenuated by scattering interaction with the intervening tissues than are photons originating closer to the surface (11). These depth-related scattering effects are not accounted for in the non-attenuation-corrected images, which appear to show high activity toward the surface and relatively low activity toward the center. CT data, in addition to imaging morphology, can be used to generate an attenuation matrix to correct this effect. Because of the lower photon energy of the CT xrays (100-140 keV), the CT-generated coefficients are scaled to reflect the attenuation of the higher-energy 511-keV positron-emission photons. Once scaled, they can be applied to the positron-emission data to yield the attenuation-corrected image. This correction process is essential for both the quantitative assessment of standardized uptake value (SUV) and improved image quality. While depth-associated attenuation correction is commonly employed in PET-only systems, integrated CT scanning provides optimized electron-density mapping amongst bone and soft-tissue regions, leading to even more precise attenuation correction. If required for enhanced image quality, contrast-CT images can best be obtained after the non-contrast CT and PET are performed. Pre-PET infusion of CT contrast may influence photon-scatter effects and confound the resulting attenuation matrix.
The differences in intrinsic spatial resolution between PET and CT cause similar problems for both independent-imagefused and integrated PET-CT scanning. Given the severalmillimeter range in tissue of the emitted positron (Table I) , and the required cross-sectional size and geometry for the "annihilation" photon detectors, the intrinsic spatial resolution of any trapped molecule of FDG is about 5-6 mm, and may be larger with other longer-range positron-emitting isotopes. How then can this lesser resolution be spatially incorporated for better delineation of the primary tumor bed and of lymphatic and metastatic spread than can be achieved by traditional medical imaging techniques alone?
Perhaps the best way to understand the benefit of incorporation of the lesser-resolution image is to consider the analogy of fusing MRI with CT data, as has become standard in delineation of the gross tumor volume (GTV) and clinical tumor volume (CTV) for planning the irradiation of brain tumors. It has been clearly shown that T2weighted MRI best demonstrates the spread of edema that delineates the accepted CTV, and that contrast-enhanced T1-weighted MRI best delineates the GTV (12). Yet, the accepted image-correlation technique involves fusing MRI sequences (consisting of 5-mm thick slices separated by 40% (2 mm) gaps) with CT sequences (consisting of 2mm thick slices with zero gap). How is this technique of incorporating the lower-resolution MRI with the higherresolution CT clinically valuable? The answer is that the more biochemically sensitive imaging of the MRI gives better information about gross and microscopic tumor volumes (GTV and CTV) than does the higher-resolution CT, but delineation of the target volumes in the CT domain permits the most accurate calculations of dose distribution in the treatment-planning process.
In a similar manner, lesser-resolution PET imaging provides important biochemical information that improves target delineation in the CT domain. With simple computer-console adjustment of the PET data parameters of SUV, the delineation of the anatomic margins of tracer uptake can be adjusted to produce a clear target outline, in a manner similar to window and level adjustment in viewing CT data.
The 3D localization of individual positron-emitting molecules is subject to the physical spatial-resolution limitations described above. However, the effective imaging resolution is improved by evaluating the density distribution of the PET data. This distribution is best envisioned via adjusting SUV to establish a visually comfortable gradient on the edges of the GTV. Although each emitted positron may travel its tissue range outward in any direction from the tracer-uptake cell before it collides with an electron and produces the annihilation-photon pair, the resulting composite photon-density distribution (derived from many emitted positrons) will always be centered at the site of the originating cell. Thereby, designation of the transitional microscopic edges of the tumor mass can be delineated to the level desired by the oncologist, and requisite CTV margins applied.
PET-CT: Clinical Applications
One of the fundamental principles of radiation oncology is to identify and delineate accurately the target for irradiation. Only then is it possible to take the steps required to irradiate aggressively the GTV and involved or suspected lymphatic pathways, while sparing normal tissues. The accurately delineated GTV and CTV also dictate the planning target volume (PTV), that volume that expands outward from the GTV or CTV to include margin for both potential microscopic spread of disease and for treatment set-up uncertainty. Furthermore, to the extent that regional lymphatic pathways should be targeted for irradiation, can tumor be shown to have already spread to that site? Or just considered to be at risk of doing so? Is there evidence of distant metastases that may alter the treatment goal from curative to palliative intent? These are fundamental clinical questions that can all be answered to a greater degree of certainty with the information provided by PET-CT.
While PET-CT is still in the relatively early stages of investigation, the preliminary data and countless examples thus far are already lending rapidly increasing support to the promise of improved 3D target delineation, as described above. Some of these findings are highlighted below.
Delineation of Primary Tumor
In one study of 39 cases (6), GTV delineation was changed significantly (at least 25% bigger or smaller GTV) in 56% of cases (22/39), when information from integrated PET was used in the planning process. GTV was increased by 25% or more in 17% of cases with head-and-neck and lung cancer, and in 33% in cancer of the pelvis. GTV was reduced by at least 25% in 33% of patients with head-and-neck cancer, 67% with lung cancer, and 19% with cancer of the pelvis. The modification of the GTV translated into altered PTV changes of greater than 20% in 46% (18/39) of cases. With the use of PET imaging, volume delineation variability between two independent oncologists decreased from a mean volume difference of 25.7 cm 3 to 9.2 cm 3 , associated with a reduction of the standard deviation from 38.3 cm 3 to 13.3 cm 3 (p = 0.02). While the impact on treatment outcome was yet to be assessed, the potential for improved 3D localization of irradiation to the tumor was demonstrated.
Exclusion of Normal Tissue and Evaluation of Regional Lymph Nodes
In another study evaluating 26 patients with stage I through III non-small cell lung cancer (9), fused images derived from separate PET and CT scanners were reviewed with the interpreting nuclear radiologist and then used to determine 3D radiation therapy target volume definitions. These target volume definitions were then compared to volumes determined from CT images alone. PET also altered radiation therapy volume in 58% of the patients, distinguishing tumor from atelectasis in the three patients with atelectasis, detecting unsuspected nodal disease in ten patients, and discovering a separate tumor focus within the same lung lobe in one patient.
Detection of Distant Metastases
In that same study (9), fused PET-CT images altered the staging estimate in 31% of the patients. The supplemental PET information was also used to detect metastatic disease in two patients, who received palliative radiation therapy as a result of the changed staging. Distant metastases have been discovered by PET in even higher frequency (16%) in other studies (6), changing the treatment strategy from curative to palliative.
Selected Case Examples
A comprehensive summary of the considerable world-wide research in the field of PET-CT is beyond the scope of this paper. The intention of this review is to describe the basicscience underpinnings, highlight some important findings in the early clinical work thus far performed, and motivate clinicians to explore the possibilities.
Listed below are just a few case examples, culled from the literature, selected to illustrate the range of useful oncology information that can only be accurately determined via either computer-assisted fused-image or integrated PET-CT (5, (8) (9) (10) 13) . The cases cited here have employed the readily available FDG tracer, but many other positron-emitting tracers are under active investigation. The list of such cases is rapidly increasing, and gives further weight to the value of this new technology:
Colon Cancer: PET-CT has been shown to be very helpful in identifying foci of tumor spread to the liver (leading to prompt resumption of chemotherapy), in the setting of rising serum carcinoembryonic antigen (CEA) levels, even when routine liver function tests and CT scans were normal. In other cases, PET-CT demonstrated that a normal-sized lymph node had been invaded by the cancer cells.
Cervical Cancer: Prior to PET-CT scanning, a patient had been treated for cervical cancer with radiation therapy and chemotherapy. The working clinical diagnosis was that moderately active cancer was still present, but localized to the cervix. The PET-CT scan revealed extensive cancer metastases to the patient's lymph nodes, and more aggressive treatment was begun immediately.
Lung Cancer:
A mass observed on a patient's left lung during a routine chest x-ray led to CT examination and biopsy. Although undetected by CT, the PET-CT scan showed mediastinal lymphatic spread, leading to a change in staging and therapy.
Lymphoma: After 16 sessions of chemotherapy for Hodgkin's disease, PET-CT scanning revealed a large area of tumor cells within the muscles under the left scapula, previously undetected by CT. Treatment was continued more aggressively.
Conclusions
The emergence of the clinical benefits of computer-assisted PET-CT image fusion and integrated scanning has quite rapidly placed this technology at the forefront of 3D conformal radiation oncology. The conformal techniques of proton therapy and IMRT have quickly ascended to the frontier of modern oncology therapy, by promising the potential for improved efficacy via aggressively irradiating tumor, while reducing side effects via minimizing dose to normal tissues. Therefore, the requirement for enhanced accuracy of target delineation and clinical tumor staging has risen hand-in-hand.
The development of high-precision PET-CT imaging has been instrumental in improving the identification of the primary tumor volume, better evaluating regional lymph nodes, and concurrently finding otherwise undetected distant metastases. Overall, PET-CT has led to better staging of both curative and palliative cases.
Although most of the clinical research thus far has used FDG, the potential use of numerous other positron-emitting tracers is under active study, and their clinical utility will likely expand quickly. Other biologically selective molecules labeled with 18 F-positron-emitting isotopes are increasingly readily available. As positron-emitting isotope-creating cyclotrons become more widely established, the door will open to greater use of tracers with shorter halflives (e.g., 11 C, 13 N, and 15 O).
The benefits of computer-assisted PET-CT image fusion have already been well established. However, the development of even higher-precision single-machine integrated scanning has moved the application of PET technology even closer to the domain of conformal radiation oncology. At this time, insurance coverage for PET-CT has been approved (by the Health Care Financing Administration, which oversees Medicare) for diagnosis, staging and re-staging for nonsmall-cell lung cancer, colorectal cancer, breast cancer, lymphoma, melanoma, esophageal cancer, most head-and-neck cancers and indeterminate solitary pulmonary nodules. Additional clinical applications currently under review include ovarian and uterine cancer, testicular cancer, pancreatic cancer, prostate cancer, and brain cancer.
